ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 23.5 | 18.7 | 16.8 |
| Other income | 0.2 | 0.2 | 0.7 |
| Total income | 23.7 | 18.9 | 17.5 |
| Profit before exceptional items & tax | -1.1 | -6.0 | -3.9 |
| Profit before tax | -1.1 | -6.0 | -3.9 |
| Net profit | -1.4 | -4.7 | -2.1 |
| Operating margin | -4.6% | -31.7% | -22.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +39.90% |
|---|
BSE results filing, NSE: ANG. Figures extracted from the filing.
ANG Lifesciences India Ltd: key numbers
- Share price
- ₹36.00
- Market cap
- ₹47.01 Cr
- Revenue (annual)
- ₹92.89 Cr
- Net profit (annual)
- ₹-11.08 Cr
- P/E (TTM)
- -3.5×Sector 43.8×
- Promoter holding
- 70.60%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from ANG Lifesciences India Ltd
All →ANG Lifesciences India Board Meeting Date
ANG Lifesciences schedules a board meeting on 14 November 2026 to approve standalone and consolidated unaudited results for the quarter and half year to 30 September 2026. Trading window stays closed until 48 hours after the results are made public.
ANG Lifesciences India Other Announcement
The company filed its quarterly shareholding pattern for the period ending September 30, 2026, as per SEBI regulations.
ANG Lifesciences India Management Change
ANG Lifesciences India Ltd announced the re-appointment of Mrs. Chetna as an Independent Director for a second five-year term, effective October 12, 2026.
ANG Lifesciences India Annual General Meeting
ANG Lifesciences India Limited held its 20th Annual General Meeting on September 30, 2026. The meeting successfully transacted routine business items.
ANG Lifesciences India Other Announcement
ANG Lifesciences India Ltd has filed its quarterly shareholding pattern as required under SEBI Regulation 31(1)(b).
ANG Lifesciences India Annual Report
ANG Lifesciences India Limited has submitted its Annual Report for the financial year 2025-26, including the notice convening its 20th Annual General Meeting.